Osteonecrosis of the Femoral Head Stem Cell Therapy Development
Osteonecrosis of the femoral head (ONFH) is a progressive disease of complex etiology and unknown pathogenesis, causing severe hip pain and dysfunction. Stem cells have been shown to have the ability to self-renew and differentiate into multiple cell types. Therefore, stem cell therapy has become one of the hip preservation options for ONFH. CD BioSciences offers stem cell therapy development services for ONFH, dedicated to advancing the treatment of this disease.
Overview of ONFH
Osteonecrosis of the femoral head (ONFH) is a progressive disease characterized by disruption of blood supply, subchondral bone necrosis, and eventually collapse of the femoral head, resulting in severe hip pain and dysfunction. The etiology of ONFH is complex and includes traumatic injury, corticosteroid treatment, alcohol abuse and connective tissue disease, ultimately leading to microcirculatory disorders. Currently, the pathology of ONFH is thought to be revelated to impaired blood supply, abnormal lipid metabolism, reduced osteogenic capacity of BMSCs, apoptosis, genetic polymorphisms and some other factors.
The total hip arthroplasty (THA) is considered as the most efficient approach for patients with ONFH in the terminal stages, but the outcomes of THA in young patients are often not excellent. Loose prosthesis, excessive wear leading to high failure rate polyethylene inserts and peri-implant infections are challenges that young patients are facing in the treatment of ONFH. With the development of biotechnology, more and more studies are focusing on the use of stem cells for the treatment of ONFH.
Stem Cell Therapy for ONFH
MSCs are one of the most commonly used stem cell subpopulations and are widely distributed in various tissues such as bone marrow, peripheral blood, adipose, and umbilical cord. Therefore, MSCs are named as bone marrow-derived MSCs (BMSCs), adipose-derived MSCs (AMSCs), peripheral blood-derived MSCs (PBMSCs), and umbilical cord-derived MSCs (UCMSCs) according to their tissue origin.
The main source of stem cells for transplantation (Xu, Yingxing et al., 2020)
Bone Marrow Mesenchymal Stem Cells
Bone marrow is the most commonly used source of stem cells for the treatment of ONFH. In a suitable environment, BMSCs can differentiate into cells of the musculoskeletal system, such as trabecular bone, articular cartilage, tendons, etc.
Adipose Mesenchymal Stem Cells
Adipose tissue is another reliable source of stem cells for the treatment of ONFH. AMSCs have several advantages such as easy access, higher productivity and similar differentiation potential as BMSCs
Peripheral Bone Marrow Stem Cells
Peripheral blood is also a source of MSCs and is considered to be superior to bone marrow. PBMSCs have many advantages over BMSCs, such as easy availability, higher cost-effectiveness, and lower risk of contamination by tumor cells.
Umbilical Cord-derived Mesenchymal Stem Cells
UCMSCs have distinct stem cell properties and lower immunogenicity. UCMSCs are also easier to isolate and expand in vitro and have a significant potential to promote tissue regeneration.
Our Services
CD BioSciences offers ONFH stem cell therapy development services. Based on our professional laboratory team and edge-cutting technologies, we can contribute to the development of stem cell therapy for ONFH. Our stem cell therapy development services for ONFH are included but not limited as follows:
- Bone Marrow Mesenchymal Stem Cell Therapy Development
- Peripheral Bone Marrow Stem Cell Therapy Development
- Adipose Mesenchymal Stem Cell Therapy Development
- Umbilical Cord-derived Mesenchymal Stem Cell Therapy Development
As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.
Reference
- Xu, Yingxing et al. "Stem cell therapy for osteonecrosis of femoral head: Opportunities and challenges." Regenerative therapy vol. 15 295-304. 28 Nov. 2020.
For research use only, not for clinical use.
